AstraZeneca plcAstraZeneca has discontinued a pivotal Phase III trial of its dual checkpoint inhibitor volrustomig in metastatic non-small cell lung cancer (NSCLC), after an independent committee concluded that the study was unlikely to meet its primary endpoints. The setback comes as the company faces growing pressure to deliver new oncology products.
Tag Archive for: NSCLC
AstraZenecaA Phase III trial evaluating AstraZeneca and Daiichi Sankyo’s potential “blockbuster” lung cancer drug Dato-DXd showed no significant improvement over standard chemotherapy. Investors reacted quickly: AstraZeneca’s share price dropped 5% following the announcement.